John A. Faucher - JPMorgan Securities LLC
Analyst
Hey, Tom. So, I guess as you think about Brazil, I guess, I understand why the trends at their current level really aren't – you expect a bounce-back. But I guess as I look at this, right, we look at the Latin-American pricing and the FX-driven pricing rolling off, where does the volume come from? Is it market share, right? Because birth rates aren't changing in that context. So as the volume improves sequentially, is it market share because U.S. brands are less uncompetitive from a pricing standpoint? Do consumers use more diapers, what have you? So does that question make sense? Why would the revenue get better as the volumes sort of need to catch up as you lose the FX-related pricing?
Thomas J. Falk - Chairman & Chief Executive Officer: So, maybe let's shift markets, John. And so we'll talk about Colombia, which has also had a big currency hit. Right? And it's not one that we usually talk about a lot because it's a relatively small market than the Indian market, but they had 20% organic growth last year, I think they were up 25% in the first quarter. And it's challenged, it's got some linkage to the oil trade, although not as much as others, but they've suffered from some of the same currency devaluation and have pulled through it. You look at Eastern Europe, what's going on in Russia and CIS. Big currency devaluation, strong price increases, some negative GDP, and yet, we're still seeing reasonably strong underlying volume growth and category demand. And so Brazil is a little bit of an outlier right now and we're trying to make sure we understand what's actually going on there from the consumer standpoint. On the tissue front, you saw in lots of markets this quarter, slight negative volume and positive price because we were pushing hard to get price in that market, especially because you're buying pulp in dollars and you've got a big transactional impact, and you've got to recover some of that to hold your P&L in shape. And that eventually will work its way through and you'll return to the more normal population-driven growth on Consumer Tissue, I think. But, yeah, I do believe that Brazil will get better, but it's probably going to be a challenging year there this year.